ADMA Biologics, Inc. (ADMA)
NASDAQ: ADMA · Real-Time Price · USD
19.85
-0.26 (-1.29%)
At close: Dec 5, 2025, 4:00 PM EST
19.69
-0.16 (-0.80%)
After-hours: Dec 5, 2025, 7:10 PM EST
ADMA Biologics Stock Forecast
Stock Price Forecast
The 2 analysts that cover ADMA Biologics stock have a consensus rating of "Strong Buy" and an average price target of $28.5, which forecasts a 43.58% increase in the stock price over the next year. The lowest target is $25 and the highest is $32.
Price Target: $28.5 (+43.58%)
Analyst Consensus: Strong Buy
* Price targets were last updated on May 8, 2025.
Analyst Ratings
The average analyst rating for ADMA Biologics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 1 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Raymond James | Raymond James | Strong Buy Maintains $25 → $32 | Strong Buy | Maintains | $25 → $32 | +61.21% | May 8, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $25 | Buy | Reiterates | $25 | +25.94% | Mar 4, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $18 → $26 | Strong Buy | Maintains | $18 → $26 | +30.98% | Nov 8, 2024 |
| Raymond James | Raymond James | Strong Buy Maintains $18 → $25 | Strong Buy | Maintains | $18 → $25 | +25.94% | Nov 8, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $18 | Strong Buy | Reiterates | $18 | -9.32% | Oct 14, 2024 |
Financial Forecast
Revenue This Year
521.08M
from 426.45M
Increased by 22.19%
Revenue Next Year
647.87M
from 521.08M
Increased by 24.33%
EPS This Year
0.60
from 0.81
Decreased by -26.12%
EPS Next Year
0.93
from 0.60
Increased by 55.68%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 536.9M | 673.6M | ||||
| Avg | 521.1M | 647.9M | ||||
| Low | 500.2M | 618.6M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 25.9% | 29.3% | ||||
| Avg | 22.2% | 24.3% | ||||
| Low | 17.3% | 18.7% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 0.63 | 1.03 | ||||
| Avg | 0.60 | 0.93 | ||||
| Low | 0.56 | 0.80 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -22.2% | 72.0% | ||||
| Avg | -26.1% | 55.7% | ||||
| Low | -31.0% | 34.3% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.